Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial
(WorldNews Denmark)

CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion on update of the EU label for Victoza®. The update is based on the results from the LEADER trial which investigated the long-term effects of Victoza® (liraglutide up to 1.8 mg) in people with type 2 diabetes, at high risk of major cardiovascular (CV) events. In the LEADER trial, Victoza® (liraglutide up to 1.8 mg) statistically significantly reduced the risk of cardiovascular death, non-fatal myocardial...